What question did this study set out to answer?

The aim is to evaluate the progress and challenges in cell-based therapies for cardiovascular disease regeneration.

August 2, 2026BiologyOpen Access

Cell-Based Therapies for Cardiac and Vascular Regeneration in Cardiovascular Disease: Recent Advances, Translational Barriers, and Future Directions

View Full Paper

Ask AI

Bookmark

The aim is to evaluate the progress and challenges in cell-based therapies for cardiovascular disease regeneration.
Review of preclinical and clinical evidence related to various cell-based regenerative strategies.
Examination of trial outcomes, including CADUCEUS, POSEIDON, and DREAM-HF.
Discussion of emerging technologies such as CRISPR-engineered iPSC lines and bioengineered cardiac patches.
CADUCEUS trial showed scar mass reduction with CDCs but no significant ejection fraction improvement.
POSEIDON trial confirmed MSC safety in a cohort of 30 patients.
DREAM-HF trial failed to meet its primary endpoint with HR 1.2 (p = 0.406) in 537 patients.

No takes yet. Share an insight, caveat, or question.

Review examines cell-based therapies for cardiac regeneration, highlighting efficacy challenges and future strategies.

Paul et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark